Effect of Cilostazol in Preventing Restenosis After Percutaneous Transluminal Coronary Angioplasty

• Published in: The American journal of cardiology Vol. 79; no. 8; pp. 1097 - 1099
• Main Authors: Take, Shunsuke, Matsutani, Masahide, Ueda, Hiroyasu, Hamaguchi, Hidehito, Konishi, Hiroki, Baba, Yuji, Kawaratani, Hitoshi, Suguira, Tetsuro, Iwasaka, Toshiji, Inada, Mitsuo
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.04.1997; Elsevier; Elsevier Limited
• Subjects: Aged; Angioplasty; Angioplasty, Balloon, Coronary; Biological and medical sciences; Blood. Blood coagulation. Reticuloendothelial system; Cilostazol; Coronary Disease - drug therapy; Coronary Disease - prevention & control; Coronary Disease - therapy; Drug therapy; Female; Humans; Male; Medical research; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Platelet Aggregation Inhibitors - therapeutic use; Recurrence; Tetrazoles - therapeutic use; Treatment Outcome; Vasodilator Agents - therapeutic use; Human; Prevention; Restenosis; Chemotherapy; Treatment; Coronary artery; Instrumentation therapy; Complication; Cilostazol; Instrumental dilatation; Antiplatelet agent
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/S0002-9149(97)00052-0

This study sought to evaluate the effect of cilostazol in preventing restenosis after successful percutaneous transluminal coronary angioplasty (PTCA) in 68 patients: 35 patients received cilostazol immediately after PTCA and 33 patients received aspirin or ticlopidine. Repeat coronary angiography was performed 4 to 6 months after PTCA and the incidence of restenosis was significantly lower (17%) in the cilostazol group than in the non-cilostazol group (40%) (p < 0.05), which indicates that cilostazol has the potential to prevent restenosis after PTCA.